BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32208298)

  • 1. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
    Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
    Grosse A; Grosse C; Rechsteiner M; Soltermann A
    Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma.
    Zhou J; Sanchez-Vega F; Caso R; Tan KS; Brandt WS; Jones GD; Yan S; Adusumilli PS; Bott M; Huang J; Isbell JM; Sihag S; Molena D; Rusch VW; Chatila WK; Rekhtman N; Yang F; Ladanyi M; Solit DB; Berger MF; Schultz N; Jones DR
    Clin Cancer Res; 2019 Dec; 25(24):7475-7484. PubMed ID: 31455678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.
    Preusser M; Berghoff AS; Koller R; Zielinski CC; Hainfellner JA; Liebmann-Reindl S; Popitsch N; Geier CB; Streubel B; Birner P
    Eur J Cancer; 2015 Sep; 51(13):1803-11. PubMed ID: 26164066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component.
    Kishi N; Ito M; Miyata Y; Kanai A; Handa Y; Tsutani Y; Kushitani K; Takeshima Y; Okada M
    Ann Surg Oncol; 2020 Mar; 27(3):945-955. PubMed ID: 31732945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
    Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
    Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
    Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
    Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
    Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
    Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
    Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of
    Yu Y; Zhang Q; Zhang J; Lu S
    J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis.
    Hou H; Zhang C; Qi X; Zhou L; Liu D; Lv H; Li T; Sun D; Zhang X
    Cancer Biol Ther; 2020; 21(1):26-33. PubMed ID: 31594446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma.
    Ito M; Miyata Y; Hirano S; Kimura S; Irisuna F; Ikeda K; Kushitani K; Kishi N; Tsutani Y; Takeshima Y; Okada M
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2325-2333. PubMed ID: 31317326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma.
    Kim IA; Hur JY; Kim HJ; Park JH; Hwang JJ; Lee SA; Lee SE; Kim WS; Lee KY
    Ann Surg Oncol; 2021 Jul; 28(7):3983-3993. PubMed ID: 33140254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.
    Zhao S; Cong X; Liu Z
    Biomed Res Int; 2021; 2021():8817898. PubMed ID: 33997043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.